Symbols

GNFT(Delisted)

Genfit·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 2

Hanging Man

Bearish Abandoned Baby

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GNFT

Genfit S.A.

A late-stage biopharmaceutical company that develops therapeutic diagnostic solutions for metabolic liver-related diseases

Industry

Established Date

Listing Date

03/27/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

180

Fiscal Year Ends

12-31

Website

www.genfit.fr

Security Type

Depository Receipts (Ordinary Shares)

Office address

Parc Eurasante, 885, avenue Eugene Avinee, 59120 Loos, France

Business

Introduction

Genfit S.A. is a late-stage clinical biopharmaceutical company dedicated to the discovery and development of innovative drug candidates and diagnostic solutions for metabolic and liver-related diseases, where there are considerable unmet medical needs. They are leaders in nuclear receptor-based drug discovery with a rich history of nearly 20 years and a strong scientific legacy.

Company Financials

EPS

GNFT has released its 2022 Q2 earnings. EPS was reported at -0.23, versus the expected 0, missing expectations. The chart below visualizes how GNFT has performed over recent quarters, highlighting trends in earnings surprises.